en
Scientific article
English

Recombinant interleukin-2 therapy of systemic lupus erythematosus in the New Zealand black/New Zealand white mouse

Published inJournal of biological response modifiers, vol. 8, no. 4, p. 366-374
Publication date1989
Abstract

New Zealand Black/New Zealand White (NZB/W) mice, a model of systemic lupus erythematosus (SLE), have age-dependent loss of interleukin-2 (IL-2) production. To determine if replacement therapy would influence the course of autoimmune disease, we injected groups of NZB/W mice with low-dose (1,500 units/day) or high-dose (15,000 units/day) purified human recombinant IL-2. Parameters of active SLE and populations of splenocytes were not altered consistently by long-term treatment with either dose of IL-2.

Keywords
  • Animals
  • Autoantibodies
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Female
  • Flow Cytometry
  • Fluorescent Antibody Technique
  • Glycoproteins/blood
  • Hematologic Tests
  • Immunoglobulins/analysis
  • Interleukin-2/administration & dosage/ therapeutic use
  • Lupus Erythematosus, Systemic/ drug therapy/mortality
  • Male
  • Mice
  • Recombinant Proteins/administration & dosage/therapeutic use
Affiliation Not a UNIGE publication
Citation (ISO format)
OWEN, K. L. et al. Recombinant interleukin-2 therapy of systemic lupus erythematosus in the New Zealand black/New Zealand white mouse. In: Journal of biological response modifiers, 1989, vol. 8, n° 4, p. 366–374.
Identifiers
ISSN of the journal0732-6580
442views
0downloads

Technical informations

Creation08/26/2010 12:36:39 PM
First validation08/26/2010 12:36:39 PM
Update time03/14/2023 4:01:40 PM
Status update03/14/2023 4:01:40 PM
Last indexation01/15/2024 9:21:24 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack